小体格患者再次经导管主动脉瓣置换术后冠状动脉通路:一项模拟研究
该研究回顾性分析254例小体格患者初次经导管心脏瓣膜植入后的CT扫描,模拟再次经导管主动脉瓣置换术(TAV-in-TAV)后冠状动脉可及性。结果45.8%患者被分类为「不可行」,CoreValve/Evolut系列不可行率显著高于SAPIEN系列(78.9% vs 26.2%,P < .001)。
要点
- 小体格患者TAV-in-TAV后冠状动脉通路「不可行」率高达45.8%。
- CoreValve/Evolut系列不可行率78.9%,显著高于SAPIEN系列的26.2%(P < .001)。
- 二叶式主动脉瓣患者不可行率低于三叶式(60.0% vs 86.2%,P = .014)。
核心结论
- 小体格患者TAV-in-TAV后冠状动脉通路「不可行」概率可能较高,尤其使用当前高框架瓣膜时,提示初次经导管心脏瓣膜植入需谨慎制定策略。
研究设计与样本
- 回顾性分析初次经导管心脏瓣膜植入后的计算机断层扫描,按瓣膜与冠状动脉位置、瓣膜至主动脉距离及瓣膜至冠状动脉距离分类患者。
- 共纳入254例患者,SAPIEN系列164例,CoreValve/Evolut系列90例;患者平均体表面积为1.44 m2。
主要发现
- 患者分类为「可行」26%、「理论可行低风险」19.7%、「理论可行高风险」8.7%、「不可行」45.8%。
- CoreValve/Evolut系列「不可行」率显著高于SAPIEN系列(78.9% vs 26.2%;P < .001)。
- SAPIEN系列中当前型号「不可行」率显著较高(SAPIEN 8.3%;SAPIENXT 1.8%;SAPIEN3 48.2%;P < .001)。
- CoreValve/Evolut系列中各代「不可行」率无显著差异(CoreValve 83.3%;Evolut R 80.0%;Evolut PRO 71.4%;P = .587)。
- 二叶式主动脉瓣患者「不可行」率低于三叶式主动脉瓣患者(60.0% vs 86.2%;P = .014)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Coronary artery access after repeat transcatheter aortic valve replacement (TAV-in-TAV) is reportedly more difficult because leaflet displacement of the first transcatheter heart valve (THV) impairs coronary cannulation; however, its effects in small patients are unknown. This study aimed to simulate coronary accessibility after TAV-in-TAV in patients of small body size. METHODS: We retrospectively analyzed computed tomography scans after initial THV implantation and classified patients by THV and coronary artery location, valve-to-aorta distance, and valve-to-coronary distance. Risks were compared between the SAPIEN and CoreValve/Evolut series, among THV generations, and between bicuspid and tricuspid aortic valves in the CoreValve/Evolut series. RESULTS: A total of 254 patients (SAPIEN series, n = 164; CoreValve/Evolut series, n = 90) were enrolled. The average body surface area of the patients was 1.44 m2. Patients were classified as "feasible" (26%), "theoretically feasible with low risk" (19.7%), "theoretically feasible with high risk" (8.7%), or "unfeasible" (45.8%). The "unfeasible" rate was significantly higher in the CoreValve/Evolut series than in the SAPIEN series (78.9% vs 26.2%; P < .001). A significantly higher "unfeasible" rate was identified in the current model of SAPIEN (SAPIEN, 8.3%; SAPIENXT, 1.8%; SAPIEN3, 48.2%; P < .001), but not in the CoreValve/Evolut series (CoreValve, 83.3%; Evolut R, 80.0%; Evolut PRO, 71.4%; P = .587). Patients with a bicuspid aortic valve had a lower "unfeasible" rate compared to those with a tricuspid aortic valve (60.0% vs 86.2%; P = .014). CONCLUSIONS: Patients of small body size may have a high probability of "unfeasible" coronary access after TAV-in-TAV, especially when treated with current high-frame devices, suggesting the need for careful strategic planning for initial THV implantation.
引用
- Kawamura A, Maeda K, Shimamura K, et al. Coronary access after repeat transcatheter aortic valve replacement in patients of small body size: A simulation study. J Thorac Cardiovasc Surg. 2022. PMID: 36604286. doi:10.1016/j.jtcvs.2022.11.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。